Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor

Novo Nordisk has dosed the first subject in a Phase I clinical trial of the oral NLRP3 inhibitor NNC6022-0001 (formerly known as VENT-01) as a potential treatment for various conditions.